Surrozen, Inc. (NASDAQ:SRZN) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: US$60M · US$31.67 a share · Morgan Stanley +2 Dealers: Morgan Stanley (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead) Buyers: Access Biotechnology; Boxer Capital Management; Perceptive Advisors; RTW Investments; Venrock Healthcare Capital Partners | Nov 13, 2026 |
| At-the-market programme of common stock Closed: US$29.8M raised Use of proceeds: Strengthening the balance sheet and supporting the expansion of the DUET Phase 2a study | Nov 9, 2026 |
| Warrant exercise of common stock warrants Closed: US$1.1M raised | Nov 9, 2026 |
| Private placement of common stock, pre-funded warrants and Series E common stock warrants Closed: US$95.1M raised · Warrants at US$11.54 Use of proceeds: Strengthen balance sheet and fund cash runway into 2029, including the DUET Phase 1b/2a study of SZN-8141 and initial Phase 1b development of SZN-8143 | Oct 20, 2026 |
| Private placement of units of common stock (or pre-funded warrants) and accompanying common stock warrants Tranche closed: US$76.4M raised · US$11.6 a unit · one half of a common stock warrant per unit · Guggenheim Securities, LLC Dealers: Guggenheim Securities, LLC (lead) Buyers: Venrock Healthcare Capital Partners (led the financing); The Column Group; Access Biotechnology; RA Capital Management; Vivo Capital; Spruce Street Capital; 5AM Ventures; Kalehua Capital; Samsara BioCapital; Acuta Capital Partners; StemPoint Capital; Braidwell LP Use of proceeds: Funds multiple ophthalmology programs through Phase 1 safety, tolerability and efficacy studies | Mar 31, 2025 |